{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009692","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.444771+00:00","generated_at":"2026-05-17T23:41:52.392676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"uniQure reports Q2 loss of $37.7M; FDA agrees on AMT-130 BLA pathway for Q1 2026 submission","bullets":["Revenue $5.3M, down from $11.1M YoY; net loss $37.7M ($0.69/share).","FDA alignment on SAP and CMC for AMT-130 BLA; topline three-year data in Sept 2025.","AMT-260 first patient showed 92% seizure reduction at 5 months with no serious AEs.","Cash $377M expected to fund operations into H2 2027.","Appointed Kylie O’Keefe as Chief Customer and Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009692","json":"https://secwatch.observer/filing/0001558370-25-009692.json","markdown":"https://secwatch.observer/filing/0001558370-25-009692.md","text":"https://secwatch.observer/filing/0001558370-25-009692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/0001558370-25-009692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:41:52.392676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}